Title : Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

Pub. Date : 2011 Nov 10

PMID : 21856867






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (> 5 cm) lymph nodes (BF-ref). fludarabine keratin 20 Homo sapiens